The NovaBridge Biosciences (NBP) SEC filings page on Stock Titan provides access to the company’s official disclosures as a foreign private issuer listed on Nasdaq. NovaBridge, formerly known as I-Mab, files reports such as Form 20-F and Form 6-K that describe its financial condition, risk factors, and operational progress as a global biotechnology platform company.
In these filings, NovaBridge outlines its business model, which combines business development and translational clinical development to advance a pipeline led by givastomig, ragistomig, uliledlimab, and VIS-101. Management’s discussion and analysis sections describe how the company allocates resources to oncology and ophthalmology programs, summarizes its collaborations with partners such as ABL Bio, and explains the structure of subsidiaries like Visara within its hub-and-spoke framework.
Investors reviewing NovaBridge’s SEC reports can examine clinical development disclosures for givastomig, including its positioning as a Claudin 18.2 x 4-1BB bispecific antibody in gastric and other gastrointestinal cancers, and for ragistomig as a PD-L1 x 4-1BB bispecific in solid tumors. Filings also discuss rights to uliledlimab outside Greater China and the VIS-101 license and assignment arrangements involving Visara and Everest Medicines.
Stock Titan enhances these regulatory documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as segment descriptions, collaboration agreements, share incentive plans, and subsequent events. Users can follow new 6-K submissions for interim updates, and consult annual filings for a more comprehensive view of NovaBridge’s strategy, risk profile, and pipeline.
By using this page, investors and researchers can monitor NovaBridge’s official SEC communications in real time, while AI-generated insights help interpret complex biotech and capital markets information contained in the original documents.
NovaBridge Biosciences director Yang Conor Chia-hung filed an initial ownership report showing two employee stock option positions tied to the company’s Ordinary Shares. One 2024 option covers 114,093 underlying Ordinary Shares at an exercise price of $1.22 per ADS-equivalent, expiring on October 1, 2034, and is fully vested and exercisable. A 2025 option covers 34,530 underlying Ordinary Shares at an exercise price of $3.86 per ADS-equivalent, expiring on October 1, 2035, and will vest in full on the first anniversary of its October 1, 2025 grant date. Footnotes note that the Ordinary Shares may be represented by ADSs, with each 10 ADSs representing 23 Ordinary Shares.
NovaBridge Biosciences officer Chu Denny Hsueh Wen filed a Form 3 as an officer of the company. The filing lists no reportable transactions, with buy, sell, acquire, dispose, exercise, gift, tax withholding, and restructuring counts all shown as zero in this excerpt.
NovaBridge Biosciences Chief Medical Officer Dennis Phillip Andrew filed an initial ownership report, listing his equity awards and share holdings. He holds 2024 employee share options over 494,510 underlying Ordinary Shares at an exercise price of 1.8200 and additional options over 186,300 underlying Ordinary Shares at 1.0500, both expiring in 2034. He also holds 92,724 restricted share units tied to Ordinary Shares and 142,740 Ordinary Shares directly. The footnotes explain that the securities may be represented by ADSs and that the options and RSUs vest over four years under specified schedules.
NovaBridge Biosciences General Counsel Lin Liwei Lorraine has filed an initial statement of beneficial ownership on Form 3 as an officer of the company. The filing identifies her role as General Counsel but does not list any stock purchases, sales, or other transactions.
NovaBridge Biosciences director and officer Fu Xi-Yong has filed an initial ownership report detailing equity interests in the company. The filing lists 2025 employee share options tied to 1,245,000 ordinary shares, with an exercise price of 1.07 per ADS and an expiration date of 2034-10-30. These options were granted on November 1, 2024 and vest in four equal annual installments starting on the first anniversary of the grant date.
The report also shows restricted share units linked to 1,245,000 underlying ordinary shares, each RSU representing a contingent right to receive one ADS that vests in four installments if the ADS achieves specified price targets. In addition, Fu Xi-Yong directly holds 59,823 ordinary shares, represented by 26,010 ADSs. Each 10 ADSs represent 23 ordinary shares of NovaBridge Biosciences.
NovaBridge Biosciences Chief Investment Officer reports initial ownership position. Zhang Xiaofan Neo reports beneficial ownership of 874,000 Ordinary Shares of NovaBridge Biosciences. According to the footnotes, these reported securities are represented by 380,000 American Depositary Shares, where each 10 ADSs represent 23 Ordinary Shares.
NovaBridge Biosciences disclosed initial insider holdings for its Chief Financial Officer, Lei Ming Kyler, through a 2025 Employee Share Option award. The option covers 996,775 underlying securities at an exercise price of 4.25 per ADS and expires on October 16, 2035.
According to the footnotes, the option was granted on October 16, 2025 and vests over five years, with 40% vesting on the second anniversary of the grant date and the remainder vesting in equal portions on each following anniversary. The filing reflects existing option holdings rather than a new market purchase or sale.
NovaBridge Biosciences executive Wu Joanna Xuqiong has reported her current equity holdings in the company. She directly holds options over 46,875 Ordinary Shares under a 2026 employee share option at an exercise price of $3.3100 per share, expiring on February 1, 2036. She also holds 24,169 Restricted Share Units that each represent a contingent right to receive one American Depositary Share, vesting over four years from a February 1, 2026 grant date. In addition, she owns 1,150 Ordinary Shares directly and 4,600 Ordinary Shares indirectly through her spouse. The ratios in the footnotes state that each 10 ADSs represent 23 Ordinary Shares, with certain reported positions represented by 500 and 2,000 ADSs.
NovaBridge Biosciences director Fu Wei filed an initial statement of beneficial ownership, detailing option awards and indirect share holdings as of 2026-03-18. He holds 2025 Employee Share Options over Ordinary Shares with exercise prices of $3.1900 per ADS-equivalent and expirations on 2035-09-03, including tranches over 1,635,729 and 2,453,583 underlying Ordinary Shares. Footnotes explain that these options vest, if at all, in eight equal quarterly installments after the issuer’s ADSs maintain 30‑trading‑day weighted average prices at or above $8.00, $12.00, and $16.00 for different grants. Indirect Ordinary Share positions are reported through entities such as CBC Investment l‑Mab Limited, IBC Investment Seven Limited, CBC SPVII Limited, C‑Bridge II Investment Ten Limited and a family trust, with each block represented by specific ADS amounts including 5,123,549, 1,583,284, 2,423,721, 1,030,237 and 3,099,950 ADSs. The filing notes that each 10 ADSs represent 23 Ordinary Shares and that Fu Wei disclaims beneficial ownership of securities held by these entities and the trust except to the extent of any pecuniary interest.
NovaBridge Biosciences director and officer Cao Sean Wuxiong filed an initial ownership report showing existing equity awards and share holdings. He reports employee share options over 19,370 Ordinary Shares at an exercise price of $1.17 per share expiring on May 28, 2035, and options over 408,929 Ordinary Shares at $4.65 per share expiring on September 3, 2035.
He also holds 408,933 restricted share units, each representing a contingent right to receive one ADS, which vest over four years from a September 3, 2025 grant date. In addition, he reports direct ownership of 56,472 Ordinary Shares. The filing reflects holdings only and does not show new open‑market purchases or sales.